Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.630
+0.010 (0.61%)
Mar 5, 2026, 4:00 PM EST - Market closed
Innate Pharma Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Innate Pharma stock have an average target of 5.00, with a low estimate of 2.00 and a high estimate of 8.00. The average target predicts an increase of 206.77% from the current stock price of 1.63.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 29, 2025.
Analyst Ratings
The average analyst rating for Innate Pharma stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +206.77% | Oct 29, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +390.83% | Oct 29, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 → $2 | Buy → Hold | Downgrades | $10 → $2 | +22.71% | Sep 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 → $11 | Strong Buy | Reiterates | $12 → $11 | +574.89% | Apr 24, 2025 |
Financial Forecast
Revenue This Year
25.82M
from 20.12M
Increased by 28.31%
Revenue Next Year
25.32M
from 25.82M
Decreased by -1.93%
EPS This Year
-0.56
from -0.61
EPS Next Year
-0.50
from -0.56
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 78.8M | 57.1M | ||||
| Avg | 25.8M | 25.3M | ||||
| Low | 8.4M | 6.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 291.4% | 121.2% | ||||
| Avg | 28.3% | -1.9% | ||||
| Low | -58.4% | -76.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.51 | -0.43 | |
| Avg | -0.56 | -0.50 | |
| Low | -0.59 | -0.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.